Siemens Healthineers has been given a "Neutral" rating by UBS, with a target price of 53 euros.
Analyst Graham Doyle has expressed concerns about the European medical technology sector, which has underperformed the overall market this year. Doyle's sales and earnings forecasts for 2025 are lower than the consensus estimates for 10 out of the 17 stocks he covers in the industry. This cautious outlook reflects the general skepticism about the sector's future performance.
The commentary was published on November 26, 2024, highlighting the challenges faced by medical technology shares in a volatile market environment.